Characteristics of Beta-blocker Treatment in Cardiac Patients with Concomitant Chronic Obstructive Pulmonary Disease

1. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4):CD003566.10.1002/14651858.CD003566.pub2871935516235327Search in Google Scholar

2. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.10.1136/bmj.d2549309148721558357Search in Google Scholar

3. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880-887.10.1001/archinternmed.2010.11220498416Search in Google Scholar

4. Hawkins NM, Petrie MC, Jhund MC, Chalmers GW, Dunn FG, McMurray JJV. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130-139.10.1093/eurjhf/hfn013263941519168510Search in Google Scholar

5. Maclay D, MacNee W. Cardiovascular disease in COPD: Mechanisms. Chest. 2013;143:798-807.10.1378/chest.12-093823460157Search in Google Scholar

6. Andell P, Koul S, Martinsson A, et al. Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction. Open Heart. 2014;1:e000002.10.1136/openhrt-2013-000002418934025332773Search in Google Scholar

7. Díez JM, Morgan JC, García RJ. The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis. 2013;8:305-312.10.2147/COPD.S31236370078423847414Search in Google Scholar

8. Zvezdin B, Milutinov S, Kojicic M, et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest. 2009;136:376-380.10.1378/chest.08-291819318666Search in Google Scholar

9. Lipworth B, Skinner D, Devereux G, et al. Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease. Heart. doi:10.1136/heartjnl-2016-309458.10.1136/heartjnl-2016-309458513668627380949Search in Google Scholar

10. Etminan M, Jafari S, Carleton B, Fitzgerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012;12:48.10.1186/1471-2466-12-48349944122947076Search in Google Scholar

11. Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis. 2007;2:535-540.Search in Google Scholar

12. Stone IS, Barnes NC, Petersen SE. Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease? Heart. 2012;98:1055-1106.Search in Google Scholar

13. Chang CL, Mills GD, McLachlan JD, Karalus NC, Hancox RJ. Cardioselective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J. 2010;40:193-200.10.1111/j.1445-5994.2009.01943.x19383058Search in Google Scholar

14. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between β-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischemic heart disease, heart failure or hypertension. Thorax. 2012;67:977-984.10.1136/thoraxjnl-2012-201945445461022941975Search in Google Scholar

15. Su VY, Chang YS, Hu YW, Hung MH, et al. Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease. Medicine (Baltimore). 2016;95:e2427.10.1097/MD.0000000000002427474887126844454Search in Google Scholar

16. Kubota Y, Asai K, Furuse E, et al. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:515-523.10.2147/COPD.S79942435670525784798Search in Google Scholar

17. Quint JK, Herrett E, Bhaskaran K, et al. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ. 2013;347:f6650.10.1136/bmj.f6650389838824270505Search in Google Scholar

18. Andell P, Erlinge D, Smith JG, et al. Beta-Blocker use and mortality in COPD patients after myocardial infarction: A Swedish Nationwide Observational Study. J Am Heart Assoc. 2015;4:e001611.10.1161/JAHA.114.001611457993725854796Search in Google Scholar

19. Ni Y, Shi G, Wan H. Use of cardioselective beta-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res. 2012;40:2051-2065.10.1177/03000605120400060223321161Search in Google Scholar

20. Farland MZ, Peters CJ, Williams JD, Bielak KM, Heidel RE, Ray SM. β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations. The Annals of Pharmacotherapy. 2013;47:651-656.10.1345/aph.1R60023585645Search in Google Scholar

21. Campo G., Pavasini R, Biscaglia S, Contoli M, Ceconi C. Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease. Eur Heart J – Cardiovasc Pharmacother. 2015;1:205-211.10.1093/ehjcvp/pvv01927533997Search in Google Scholar

22. Wellstein A, Palm D, Belz GG. Affinity and selectivity of beta-adrenoceptor antagonists in vitro. J Cardiovasc Pharmacol. 1986;8Suppl11:S36-S40.10.1097/00005344-198511001-000062439796Search in Google Scholar